CalciMedica, Inc. (CALC) - 10-K Filing Summary
Business Context and Reporting Period
Company: CalciMedica, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: CalciMedica is a clinical-stage biopharmaceutical company developing therapeutics targeting calcium release-activated calcium (CRAC) channels. The company focuses on treating acute critical illnesses (e.g., acute pancreatitis, acute kidney injury) and chronic inflammatory diseases. Its lead product candidate is Auxora (zegocractin), an intravenous CRAC channel inhibitor.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 Value | 2023 Value |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(13.7) million | $(34.4) million |
| Total Operating Expenses | $24.2 million | $38.1 million |
| Research & Development (R&D) | $14.5 million | $15.9 million |
| General & Administrative (G&A) | $9.7 million | $22.2 million |
| Cash, Cash Equivalents & Short-Term Investments | $18.7 million | $11.2 million |
| Accumulated Deficit | $(159.8) million | $(146.1) million |
| Net Cash Used in Operating Activities | $(21.1) million | $(25.7) million |
Note: The company has never generated revenue from product sales. The reduction in net loss in 2024 was primarily driven by a $9.5 million gain from the fair value adjustment of warrant liabilities and a significant decrease in G&A expenses due to the absence of one-time merger-related charges present in 2023.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 36% ($13.9 million) compared to 2023. G&A expenses dropped 56% ($12.5 million), largely because 2023 included $10.5 million in one-time stock option acceleration charges and $5.7 million in severance charges related to the 2023 reverse merger with Graybug Vision, Inc.
- Capital Raises: In 2024, the company raised approximately $29.2 million in gross proceeds through a private placement ($20.4 million) and an underwritten public offering ($10.2 million).
- Warrant Liability Gain: Other income increased significantly to $10.5 million in 2024 (from $3.7 million in 2023), driven by a $9.5 million gain from the fair value adjustment of warrant liabilities associated with the 2024 private placement.
Guidance, Outlook, and Risks
Clinical Pipeline & Milestones:
- Auxora in Acute Kidney Injury (AKI): The Phase 2 "KOURAGE" trial is ongoing. Data is expected around the end of 2025.
- Auxora in Acute Pancreatitis (AP): The Phase 2b "CARPO" trial is complete. The company plans an End-of-Phase 2 meeting with the FDA in mid-2025 and aims to initiate a Phase 3 program by the end of 2025, pending funding.
- Auxora in AIPT: The Phase 1/2 "CRSPA" trial in pediatric patients is ongoing, with an update expected in the second half of 2025.
Liquidity and Funding:
- As of December 31, 2024, the company held $18.7 million in cash and investments.
- Subsequent Financing: On February 28, 2025, the company entered into a Loan and Security Agreement with Avenue Venture Opportunities Fund for up to $32.5 million. An initial tranche of $10.0 million was funded on March 3, 2025.
- Management believes current resources, including the new loan, will fund operations through mid-2026. However, additional capital will be required to complete development and commercialization.
Key Risks:
- Capital Requirements: The company has a history of net losses and requires substantial additional funding. Failure to raise capital could force delays or termination of clinical programs.
- Clinical Uncertainty: Results from early trials are not always predictive of later-stage success. Regulatory approval is not guaranteed.
- Debt Covenants: The 2025 Loan Agreement includes restrictive covenants and a maturity date of September 1, 2028. Default could result in immediate repayment demands.
- Manufacturing Reliance: The company relies entirely on third-party contract manufacturers, including a single-source supplier in China for certain components.
Investor Verification Checklist
- Cash Runway: Verify the exact burn rate and confirm the sufficiency of the $18.7 million cash balance plus the $10 million loan tranche to reach the mid-2026 milestone without further dilution.
- Loan Terms: Review the specific milestones required to trigger Tranche 2 ($7.5M) and Tranche 3 ($15M) of the Avenue Venture loan, as well as the interest rate floor (12.75%).
- Phase 3 Feasibility: Assess the likelihood of securing the additional funding required to initiate the Phase 3 trial for Acute Pancreatitis, which is contingent on the mid-2025 FDA meeting.
- Warrant Liability: Monitor the fair value of outstanding warrant liabilities (Tranche B), as fluctuations in stock price will continue to impact reported net income/loss.
- Supply Chain: Confirm the status of the single-source supplier in China and any contingency plans for supply chain disruption.